FoxOs in Tumor Suppression and Stem Cell Maintenance  by Arden, Karen C.
Leading Edge
PreviewsFoxOs in Tumor Suppression and Stem 
Cell Maintenance
Karen C. Arden1,*
1Ludwig Institute for Cancer Research and Department of Medicine, University of California, San Diego, School of Medicine, La 
Jolla, CA 92093, USA
*Correspondence: karden@ucsd.edu
DOI 10.1016/j.cell.2007.01.009
The FoxO transcription factors have been implicated in many processes including tumor 
suppression and cell death. In this issue, two groups now report on mice that conditionally 
lack the three predominant FoxO transcription factors. Tothova et al. (2007) demonstrate that 
FoxOs are critical for the long-term maintenance of hematopoietic stem cells, and Paik et al. 
(2007) show that FoxOs suppress the formation of hemangiomas and lymphomas in mice.The three principal members of the 
mammalian FoxO subfamily of Fox 
transcription factors (FoxO1, FoxO3, 
and FoxO4) were first discovered 
through the cloning of chromosomal 
translocation breakpoints associ-
ated with tumors (reviewed in Arden, 
2006). FoxOs have since been stud-
ied through manipulation of cultured 
cells and in worms, flies, and mice 
(reviewed in Greer and Brunet, 2005). 
They are important in a variety of 
processes including cellular differen-
tiation, tumor suppression, metabo-
lism, cell-cycle arrest, cell death, 
and protection from stress. In mice, 
the individual disruption of each of 
the three FoxO genes results in dif-
ferent phenotypes, suggesting some 
degree of functional diversification 
during development (Castrillon et al., 
2003, Hosaka et al., 2004). Yet the 
three genes have overlapping pat-
terns of expression and all three bind 
to the same DNA target sequence. 
Thus, the FoxOs may be capable of 
regulating the same target genes 
and so may have overlapping func-
tions. To address this possibility, two 
groups now report in this issue the 
consequences of the conditional and 
simultaneous disruption of both alle-
les of the three principal FoxO genes 
in mice (Paik et al., 2007; Tothova et 
al. 2007).
Paik et al. (2007) describe the phe-
notype of animals in which Cre-medi-
ated gene disruption of all three FoxO 
genes was induced at 4 to 5 weeks of age. Between 19 and 30 weeks of age 
the animals developed lymphoblastic 
thymic lymphomas that were capable 
of spreading to the spleen, liver, and 
lymph nodes (Table 1). In addition, as 
early as 6 to 8 weeks of age, mice also 
developed widespread hemangiomas 
starting in the uterus that progress to 
massive fatal hemangiomas affect-
ing numerous tissues. In 9% of the 
animals the lesions progressed to 
lethal angiosarcomas. Loss of all 
three FoxO alleles is required for the 
full tumor phenotype, as disruption 
of any two of the three FoxO genes 
resulted in a less severe phonotype. 
This confirms that there is functional 
redundancy among these closely 
related transcription factors.
Given the widespread tissue 
distribution of FoxO expression in 
mammals it is somewhat surprising 
that the tumor phenotype of these 
mice is restricted to only certain 
tissues. The chromosome trans-
locations that disrupt the human Cell 128, JaFOXO gene have been associated 
with leukemia and the solid tumor 
alveolar rhabdomyosarcoma, and 
misregulation of FOXOs has been 
associated with a variety of tumor 
types, including those of the pros-
tate, stomach, brain, and breast. 
Because the FOXO DNA-binding 
domain is disrupted by the chro-
mosomal translocations it has been 
proposed that FoxOs may function 
as tumor suppressors. As would 
be expected of a tumor-suppres-
sor gene, activation of FoxO factors 
by mutation of the phosphorylation 
sites (thereby restricting the locali-
zation of the FOXO proteins to the 
nucleus) leads to cell-cycle arrest 
or cell death. Furthermore, all three 
FoxO factors are directly regulated 
by AKT, and the tumor spectrum 
resulting from mutations affecting 
the PI3K/AKT pathway produce a 
variety of tumor types. Thus, it is 
surprising that, despite the absence 
of FoxO in several cell and tissue Table 1. Phenotypes of the FoxO1, FoxO3, FoxO4 Conditional 
Knockout Mouse
Tissue Phenotype
Bone Marrow Decrease in long-term hematopoietic stem cell population due 
to increased entry into cell cycle, decreased renewal capacity, 
increased apoptosis, and an increase in reactive oxygen species. 
Vasculature Uterine hemangiomas appear at 6 to 8 weeks of age, followed 
by widespread fatal hemangiomas in skeletal muscle, abdominal 
wall, liver, adrenal glands, bone marrow, lymph nodes, and skin. 
Thymus Thymic lymphomas appear at 19 to 30 weeks of age; they may 
subsequently spread to spleen, liver, and lymph nodes.nuary 26, 2007 ©2007 Elsevier Inc. 235
types where FoxOs are normally 
expressed, the tumor phenotype 
was restricted to thymocytes and 
endothelial-derived cells. 
Remarkably, not all tissues con-
taining endothelial cells developed 
hemangiomas. For example, lungs 
and kidneys remained unaffected, 
suggesting that the phenotype is 
not only restricted to particular cell 
lineages but is also organ specific. 
A closer look at the differences 
between cell types revealed that 
FoxO-deficient endothelial cells 
derived from the liver, like FoxO-defi-
cient thymocytes, have an increased 
ability to proliferate and survive. 
These aberrant characteristics were 
absent in FoxO-deficient endothelial 
cells derived from lung tissue. When 
these two cell types were subjected 
to gene expression profile studies, 
138 genes were identified as dif-
ferentially expressed. Genes likely 
to be direct FoxO targets were pre-
dicted using an in silico approach to 
identify known FoxO-binding motifs. 
This process narrowed the list to 21 
genes, 12 of which could be vali-
dated by more than one method. 
The most significant change in gene 
expression found in the FoxO-defi-
cient endothelial cells of the liver 
compared to those of the lung is 
the downregulation of Sprouty2, a 
protein known to inhibit growth fac-
tor signaling. The authors establish 
Sprouty2 as a negative regulator 
of endothelial cell proliferation and 
survival and a major effector of 
FoxO function in the endothelium. 
Interestingly, the same in silico 
approach, when applied to FoxO-
deficient thymocytes (the thymus 
being the other tissue from which 
tumors originated), produced a 
nonoverlapping list of putative 
direct targets further reinforcing 
the concept of FoxO cell and tis-
sue type specificity. Although much 
remains to be elucidated concern-
ing the role of FoxOs in tumorigen-
esis, this report lays an invaluable 
groundwork for future studies.
The work by Tothova et al. (2007) 
implicates FoxOs as important 
mediators of the cellular response 
to oxidative stress, which is involved 236 Cell 128, January 26, 2007 ©2007 Ein the etiology of many human dis-
eases. Using the same system as 
Paik et al. to disrupt all three FoxO 
genes, Tothova et al. focused on 
the hematopoietic system. They 
detected a significant decrease in 
the population of long-term hemat-
opoietic stem cells (HSCs) and in 
the common lymphoid progeni-
tor compartment. The FoxO-defi-
cient bone marrow was defective 
in colony formation activity in vitro 
and in its ability to support long-
term bone marrow repopulation in 
vivo while short-term repopulation 
activity was slightly increased. The 
authors also found a significant 
increase in the number of HSCs, 
but not myeloid progenitors, exiting 
G0/G1 and entering S/G2/M, sug-
gesting that FoxOs are important in 
maintaining HSCs in the quiescent 
state, thereby preserving their rep-
licative and self-renewal capacity. 
The FoxO-deficient HSCs also dis-
play an increased level of apoptosis 
further contributing to the aberrant 
decrease in cell number. Unlike the 
cell-cycle phenotype, the increase 
in apoptosis was not restricted to 
HSCs but was also detected in more 
mature populations as well. Corrob-
orating the functional redundancy 
of FoxO proteins observed by Paik 
et al., deficiency in any one or two 
FoxO genes in combination does 
not produce the full cell cycle and 
apoptotic phenotype. FOXO4 had 
previously been shown to play a role 
in the resistance of quiescent cells 
to reactive oxygen species (Kops 
et al., 2002). Tothova et al. found 
a marked increase in the levels of 
reactive oxygen species in HSCs 
isolated from the FoxO-deficient 
mice. Gene expression analysis, 
focusing on genes involved in the 
metabolism of reactive oxygen spe-
cies, revealed a decrease in expres-
sion of a subset of genes associated 
with the cellular response to oxida-
tive stress. This suggests that the 
increase in reactive oxygen species 
detected in the HSCs is due to a defi-
ciency in gene products required for 
the detoxification of reactive oxygen 
species. In fact, daily treatment of 
the FoxO-deficient animals with lsevier Inc.the antioxidant N-acetyl-L-cysteine 
resulted in the complete reversion 
of the HSC phenotype.
The two reports have much in com-
mon. Both support the idea that the 
effect of FoxO deficiency is highly 
dependent on context. Furthermore, 
in both cases, loss of FoxOs pro-
moted entry into the cell cycle with 
different outcomes. Unrestricted pro-
liferation of thymocytes and endothe-
lial cells produced a tumor phenotype 
whereas HSCs exit from a quiescent 
state and terminally differentiate, elim-
inating the capacity for long-term self-
renewal. Interestingly, the two studies 
report opposite effects on apoptosis 
in the different FoxO-deficient cell 
types. There was a decrease in apop-
tosis in FoxO-deficient endothelial 
cells and thymocytes, whereas an 
increase in apoptosis was observed 
in FoxO-deficient HSCs. The results 
described by Tothova et al. suggest 
that FoxOs may play a more general 
role in maintaining stem cell potential. 
FoxO3 is important in maintaining a 
quiescent pool of ovarian follicles. In 
FoxO3-deficient mice, reduced fer-
tility in females is a result of uniform 
activation of follicle maturation and 
degeneration in the ovary. In broader 
terms, this ability to maintain a qui-
escent state is reminiscent of the role 
that the C. elegans FoxO ortholog, 
Daf-16, plays in entering and main-
taining the dauer state of develop-
mental arrest during which the worms 
develop impermeable cuticles and 
are nonfeeding for up to 3 months.
Although these two reports make a 
significant contribution to our under-
standing of the importance of FoxOs 
at the organismal level many ques-
tions remain to be explored. Why 
does disruption of FoxO produce 
such a restricted tumor phenotype? 
What other factors contribute to the 
context-dependant effects of FoxO 
deficiency? As FoxO proteins play 
a role in longevity, how might main-
tenance of stem cell populations 
and protection from stress have an 
impact on life span? How might these 
differences be exploited for the treat-
ment of disease? Molecules exist that 
maintain FoxO nuclear localization, 
and thus maintain FoxO activity (Kau 
et al., 2003; Schroeder et al., 2005), 
but whether any of these compounds 
will surmount the significant obstacles 
required to enter the clinic remains 
to be seen. The important findings 
reported by Paik et al. and Tothova et 
al. have substantially contributed to 
our understanding of FoxO proteins 
and illuminate the complexity of their 
function. Moreover, the generation of 
these animals in which FoxO inactiva-
tion can be executed in a controlled 
manner will allow other fundamental 
questions to be addressed.Cell motility is a complex biological 
process that requires the precisely 
coordinated function of numerous 
cellular proteins. Fundamentally, 
motility requires two elements—sig-
nal transduction pathways that are 
activated in response to stimuli that 
induce motility and cellular compo-
nents that mediate the mechanical 
aspects of motility. With regard to 
signaling pathways, much evidence 
supports an essential role for some 
of the Rho-family GTPases (and 
many of their upstream regulators 
and downstream effectors) as well 
as several receptor kinases, G pro-
tein-coupled receptors, and a vari-
ety of additional intracellular signal-
ing proteins and scaffolds. Among 
the many proteins required for the 
mechanical aspects of cell motil-
ity are components of the actomy-
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osin cytoskeleton, microtubules, 
integrins, and a variety of cytoskel-
etal binding proteins. Numerous 
studies have begun to elucidate sig-
naling pathways that link cell sur-
face receptors (engaged by known 
chemotactic ligands) and integrins 
to intracellular pathways that pro-
mote the coordinated cytoskeletal 
reorganization required for proper 
cell movement. In addition to the 
various cell-migration proteins that 
have been linked to specific cellu-
lar pathways, there are additional 
proteins that appear to be required 
for motility but whose specific 
function has been elusive. A good 
example of such a class of proteins 
is the family of guanylyl cyclases, 
which catalyze the conversion of 
GTP to the second messenger 
cyclic GMP (cGMP). In particular, 
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the transmembrane subclass of 
guanylyl cyclases—whose activity 
can be modulated by intracellular 
signals via membrane-associated 
receptors—has been implicated 
in chemotactic cell migration and 
axon guidance (Ayoob et al., 2004; 
Bosgraaf et al., 2002). Moreover, 
cGMP has also been implicated 
in cell motility, along with a few 
cGMP-dependent kinases and 
phosphodiesterases (Postma et 
al., 2004). However, a signaling 
pathway wherein guanylyl cyclases 
are activated in the context of cell 
migration has not been established. 
In this issue, Guo et al. (2007) reveal 
a signaling link between the Rac 
GTPase and the transmembrane 
guanylyl cyclases that mediates 
growth factor-induced migration of 
fibroblasts.
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